Cosio Terenzio, Di Prete Monia, Gaziano Roberta, Lanna Caterina, Orlandi Augusto, Di Francesco Paolo, Bianchi Luca, Campione Elena
Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Anatomic Pathology Unit, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Biomedicines. 2021 Feb 26;9(3):237. doi: 10.3390/biomedicines9030237.
Retinoids have numerous applications in inflammatory, dyskeratotic, and oncohematology diseases. Retinoids have now reached the fourth generation, progressively reducing toxicity whilst increasing their efficacy. Trifarotene is a new fourth-generation retinoid with a selective action on RAR-γ. In this review, we reported the trials-both concluded and in progress-including the use of trifarotene in dermatological diseases. Studies were identified by searching electronic databases (MEDLINE, EMBASE, PubMed, Cochrane, Trials.gov) from 2012 to today and reference lists of respective articles. Only articles published in English language were included. Randomized trials evaluating trifarotene tolerability, safety, and efficacy in congenital ichthyosis and acne have demonstrated great results and mild side effects, leading to the approval by the FDA of trifarotene for the treatment of lamellar ichthyosis in 2014, and of acne vulgaris in October 2019. No high-quality randomized clinical trials have evaluated the treatment of primary cutaneous lymphomas with trifarotene. Finally, we are hypothesizing future perspectives in the treatment of non-melanoma skin cancers, fungal infections, photoaging, and hand-foot skin reactions with trifarotene.
维甲酸在炎症性、角化异常性和血液肿瘤学疾病中有众多应用。维甲酸现已发展到第四代,在降低毒性的同时逐渐提高其疗效。曲法罗汀是一种新型的第四代维甲酸,对维甲酸受体γ(RAR-γ)具有选择性作用。在本综述中,我们报告了已完成和正在进行的试验,包括曲法罗汀在皮肤病中的应用。通过检索2012年至今的电子数据库(MEDLINE、EMBASE、PubMed、Cochrane、Trials.gov)以及各文章的参考文献列表来确定研究。仅纳入以英文发表的文章。评估曲法罗汀在先天性鱼鳞病和痤疮中的耐受性、安全性和疗效的随机试验已取得了良好结果且副作用轻微,这使得曲法罗汀在2014年获得美国食品药品监督管理局(FDA)批准用于治疗板层状鱼鳞病,并于2019年10月获批用于治疗寻常痤疮。尚无高质量的随机临床试验评估曲法罗汀治疗原发性皮肤淋巴瘤的效果。最后,我们推测了曲法罗汀在治疗非黑素瘤皮肤癌、真菌感染光老化和手足皮肤反应方面的未来前景。